TEVA LAUNCHES VARENICLINE TEVA FOR SMOKING CESSATION
Teva Pharmaceuticals is pleased to announce the launch of Varenicline Teva, a generic prescription medication indicated for smoking cessation.
Varenicline Teva works by targeting nicotine receptors in the brain, reducing cravings and withdrawal symptoms associated with quitting smoking.
For any queries or further information, please contact your local Teva representative.
Product information is available upon request or from the SmPC available at HPRA.ie.
Adverse events should be reported. Reporting forms and information can be found at www.hpra.ie. Adverse events should also be reported to Teva UK Limited on +44 (0) 207 540 7117 or medinfo@tevauk.com.
Date of preparation: December 2024
Job code: Vcli-IE-00013
Read more Product News